Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Scynexis Inc (SCYX)

Scynexis Inc (SCYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 73,671
  • Shares Outstanding, K 37,780
  • Annual Sales, $ 140,140 K
  • Annual Income, $ 67,040 K
  • 60-Month Beta 1.52
  • Price/Sales 0.54
  • Price/Cash Flow 1.05
  • Price/Book 1.02
Trade SCYX with:

Options Overview Details

View History
  • Implied Volatility 87.99% ( +21.21%)
  • Historical Volatility 67.45%
  • IV Percentile 15%
  • IV Rank 4.08%
  • IV High 923.84% on 06/24/24
  • IV Low 52.41% on 05/28/24
  • Put/Call Vol Ratio 1.50
  • Today's Volume 5
  • Volume Avg (30-Day) 56
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 1,413
  • Open Int (30-Day) 2,374

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.19
  • Number of Estimates 1
  • High Estimate -0.19
  • Low Estimate -0.19
  • Prior Year 2.46
  • Growth Rate Est. (year over year) -107.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7500 +11.43%
on 06/21/24
2.5965 -24.90%
on 06/03/24
-0.4650 (-19.25%)
since 05/31/24
3-Month
1.3700 +42.34%
on 04/17/24
3.0700 -36.48%
on 05/20/24
+0.5000 (+34.48%)
since 04/02/24
52-Week
1.3500 +44.44%
on 03/19/24
3.8700 -49.61%
on 09/05/23
-1.0000 (-33.90%)
since 06/30/23

Most Recent Stories

More News
Scynexis: Q1 Earnings Snapshot

Scynexis: Q1 Earnings Snapshot

SCYX : 1.9500 (unch)
Scynexis: Q3 Earnings Snapshot

Scynexis: Q3 Earnings Snapshot

SCYX : 1.9500 (unch)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX). Such investors are...

SCYX : 1.9500 (unch)
The Law Offices of Frank R. Cruz Announces Investigation of SCYNEXIS, Inc. (SCYX) on Behalf of Investors

/PRNewswire/ -- The Law Offices of Frank R. Cruz announces an investigation of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX) on behalf of...

SCYX : 1.9500 (unch)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX). Such investors are...

SCYX : 1.9500 (unch)
Scynexis: Q2 Earnings Snapshot

Scynexis: Q2 Earnings Snapshot

SCYX : 1.9500 (unch)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating SCYNEXIS, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

SCYX : 1.9500 (unch)
Scynexis: Q1 Earnings Snapshot

Scynexis: Q1 Earnings Snapshot

SCYX : 1.9500 (unch)
SCYNEXIS (NASDAQ: SCYX) Enters Into Exclusive Agreement with GSK (NYSE: GSK) to Continue Commercializing Brexafemme to Treat Fungal Infections

SCYNEXIS, Inc. (NASDAQ: SCYX) operates as a biotechnology company, which is focused on the research and development of novel solutions

SCYX : 1.9500 (unch)
GSK : 38.21 (-0.44%)
Scynexis: Q3 Earnings Snapshot

Scynexis: Q3 Earnings Snapshot

SCYX : 1.9500 (unch)

Business Summary

SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening...

See More

Key Turning Points

3rd Resistance Point 2.1335
2nd Resistance Point 2.0767
1st Resistance Point 2.0134
Last Price 1.9500
1st Support Level 1.8933
2nd Support Level 1.8365
3rd Support Level 1.7732

See More

52-Week High 3.8700
Fibonacci 61.8% 2.9074
Fibonacci 50% 2.6100
Fibonacci 38.2% 2.3126
Last Price 1.9500
52-Week Low 1.3500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar